Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis.
Siddharth M PatelYu Mi KangKyungAh ImBrendon L NeuenStefan D AnkerDeepak L BhattJaved ButlerDavid Z I CherneyBrian Lee ClaggettRobert A FletcherWilliam G HerringtonCatherine M ViscoliMeg J JardineKenneth W MahaffeyDarren K McGuireJohn Joseph Valentine McMurrayBruce C NealMilton PackerVlado PerkovicScott D SolomonNatalie StaplinMuthiah VaduganathanChristoph WannerDavid Collins WheelerFaiez ZannadYujie ZhaoHiddo J Lambers HeerspinkMarc S SabatineStephen D WiviottPublished in: Circulation (2024)
SGLT2i reduce the risk of MACE across a broad range of patients irrespective of atherosclerotic cardiovascular disease, diabetes, kidney function, or other major clinical characteristics at baseline. This effect is driven primarily by a reduction of cardiovascular death, particularly HF death and sudden cardiac death, without a significant effect on myocardial infarction in the overall population, and no effect on stroke. These data may help inform selection for SGLT2i therapies across the spectrum of cardiovascular-kidney-metabolic disease.
Keyphrases
- cardiovascular disease
- systematic review
- type diabetes
- newly diagnosed
- heart failure
- end stage renal disease
- atrial fibrillation
- ejection fraction
- emergency department
- randomized controlled trial
- metabolic syndrome
- prognostic factors
- insulin resistance
- left ventricular
- electronic health record
- artificial intelligence
- meta analyses
- big data
- blood brain barrier
- skeletal muscle
- cardiovascular risk factors
- adverse drug